The newly published report by IMARC Group, titled, ”Pulmonary Embolism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the pulmonary embolism market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the market. The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Pulmonary embolism (PE) represents a condition that can cause damage to the lungs and reduce the amount of oxygen reaching the vital organs. Some of the common symptoms of PE include shortness of breath, coughing up blood, chest pain, etc. Numerous other indications may consist of light-headedness, increased heartbeat, leg swelling, etc. Diagnosis of pulmonary embolism generally involves a combination of tests, including a CT scan, chest X-ray, blood tests, etc. It is treated by using blood thinners, such as warfarin or heparin, to dissolve the blood clot and prevent further clots from forming.
Request a Free Sample Report: https://www.imarcgroup.com/pulmonary-embolism-market/requestsample
The growing incidences of certain inflammatory conditions, including lupus and rheumatoid arthritis, and the expanding obese population are primarily driving the pulmonary embolism market. Additionally, the increasing prevalence of various associated risk factors, such as patients undergoing chemotherapy and addiction to smoking, and the widespread adoption of supplemental estrogen and hormone replacement therapy are further catalyzing the market growth.
Besides this, the rising utilization of thrombolytic treatment to break up existing blood clots for treating individuals with severe lung damage is acting as another significant growth-inducing factor. Moreover, the inflating popularity of vena cava filters among patients who are unable to take anticoagulant medicines is positively influencing the global market. Apart from this, the escalating demand for compression stockings to prevent the formation of blood clots is also stimulating the market growth. Furthermore, the development of direct oral anticoagulants (DOACs), which do not require regular monitoring, is anticipated to fuel the pulmonary embolism market over the forecasted period.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the pulmonary embolism market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the pulmonary embolism market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC List of figures: https://www.imarcgroup.com/pulmonary-embolism-market
Key Questions Answered in this Report:
- How has the pulmonary embolism market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the pulmonary embolism market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the pulmonary embolism market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Browse the Latest Research Report:
Adeno-associated Virus Gene Therapy Market Report 2023-2033
Atrial Flutter Market Report 2023-2033
LAG 3 Next Generation Immunotherapy Market Report 2023-2033
Guillain-Barre Syndrome Market Report 2023-2033
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
